SK140594A3 - Manufacture and application of non-immunogenic enzymatic pharmaceutical agents isolated from antarctic krill - Google Patents
Manufacture and application of non-immunogenic enzymatic pharmaceutical agents isolated from antarctic krill Download PDFInfo
- Publication number
- SK140594A3 SK140594A3 SK1405-94A SK140594A SK140594A3 SK 140594 A3 SK140594 A3 SK 140594A3 SK 140594 A SK140594 A SK 140594A SK 140594 A3 SK140594 A3 SK 140594A3
- Authority
- SK
- Slovakia
- Prior art keywords
- treatment
- phim
- days
- infections
- patients
- Prior art date
Links
- 241000239366 Euphausiacea Species 0.000 title claims abstract description 51
- 230000002163 immunogen Effects 0.000 title claims description 11
- 238000004519 manufacturing process Methods 0.000 title abstract description 3
- 230000002255 enzymatic effect Effects 0.000 title description 5
- 239000008177 pharmaceutical agent Substances 0.000 title 1
- 238000011282 treatment Methods 0.000 claims abstract description 198
- 230000000694 effects Effects 0.000 claims abstract description 52
- 102000004190 Enzymes Human genes 0.000 claims abstract description 32
- 108090000790 Enzymes Proteins 0.000 claims abstract description 32
- 239000000203 mixture Substances 0.000 claims abstract description 31
- 102000018389 Exopeptidases Human genes 0.000 claims abstract description 19
- 108010091443 Exopeptidases Proteins 0.000 claims abstract description 19
- 108010059378 Endopeptidases Proteins 0.000 claims abstract description 13
- 102000005593 Endopeptidases Human genes 0.000 claims abstract description 13
- 208000002193 Pain Diseases 0.000 claims description 74
- 230000036407 pain Effects 0.000 claims description 72
- 208000015181 infectious disease Diseases 0.000 claims description 66
- 206010028980 Neoplasm Diseases 0.000 claims description 61
- 230000004054 inflammatory process Effects 0.000 claims description 43
- 206010061218 Inflammation Diseases 0.000 claims description 42
- 238000002360 preparation method Methods 0.000 claims description 21
- 201000011510 cancer Diseases 0.000 claims description 18
- 238000000576 coating method Methods 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 12
- 208000003251 Pruritus Diseases 0.000 claims description 10
- 230000007803 itching Effects 0.000 claims description 10
- 206010006451 bronchitis Diseases 0.000 claims description 7
- 206010040954 Skin wrinkling Diseases 0.000 claims description 5
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 5
- 208000038016 acute inflammation Diseases 0.000 claims description 5
- 230000006022 acute inflammation Effects 0.000 claims description 5
- 201000005917 gastric ulcer Diseases 0.000 claims description 5
- 208000037062 Polyps Diseases 0.000 claims description 4
- 208000010668 atopic eczema Diseases 0.000 claims description 4
- 230000001580 bacterial effect Effects 0.000 claims description 4
- 230000037303 wrinkles Effects 0.000 claims description 4
- 201000004384 Alopecia Diseases 0.000 claims description 3
- 208000010412 Glaucoma Diseases 0.000 claims description 3
- 230000000172 allergic effect Effects 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 3
- 208000022873 Ocular disease Diseases 0.000 claims description 2
- 208000014617 hemorrhoid Diseases 0.000 claims description 2
- 208000004396 mastitis Diseases 0.000 claims description 2
- 201000009240 nasopharyngitis Diseases 0.000 claims description 2
- 230000001747 exhibiting effect Effects 0.000 claims 7
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 3
- 229910052802 copper Inorganic materials 0.000 claims 3
- 239000010949 copper Substances 0.000 claims 3
- 230000003511 endothelial effect Effects 0.000 claims 2
- 239000005749 Copper compound Substances 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 150000001880 copper compounds Chemical class 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 208000002064 Dental Plaque Diseases 0.000 abstract description 4
- 229940088598 enzyme Drugs 0.000 description 67
- 210000004027 cell Anatomy 0.000 description 50
- 239000000243 solution Substances 0.000 description 45
- 208000027418 Wounds and injury Diseases 0.000 description 41
- 241000700159 Rattus Species 0.000 description 39
- 206010052428 Wound Diseases 0.000 description 37
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 37
- 238000002347 injection Methods 0.000 description 32
- 239000007924 injection Substances 0.000 description 32
- 241000282414 Homo sapiens Species 0.000 description 28
- 238000007920 subcutaneous administration Methods 0.000 description 25
- 238000000034 method Methods 0.000 description 24
- 239000000843 powder Substances 0.000 description 21
- 206010067482 No adverse event Diseases 0.000 description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 20
- 206010042674 Swelling Diseases 0.000 description 20
- 230000008961 swelling Effects 0.000 description 20
- 239000003708 ampul Substances 0.000 description 19
- 230000001338 necrotic effect Effects 0.000 description 19
- 206010067484 Adverse reaction Diseases 0.000 description 18
- 206010015150 Erythema Diseases 0.000 description 18
- 230000006838 adverse reaction Effects 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 17
- 239000004599 antimicrobial Substances 0.000 description 16
- 239000003755 preservative agent Substances 0.000 description 16
- 235000018102 proteins Nutrition 0.000 description 16
- 239000011780 sodium chloride Substances 0.000 description 16
- 230000002354 daily effect Effects 0.000 description 15
- 102000035195 Peptidases Human genes 0.000 description 14
- 210000000214 mouth Anatomy 0.000 description 14
- 241000282472 Canis lupus familiaris Species 0.000 description 13
- 208000001388 Opportunistic Infections Diseases 0.000 description 13
- 108091005804 Peptidases Proteins 0.000 description 13
- 239000005018 casein Substances 0.000 description 13
- 235000021240 caseins Nutrition 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 230000001154 acute effect Effects 0.000 description 12
- 230000037396 body weight Effects 0.000 description 12
- 239000011248 coating agent Substances 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 230000002980 postoperative effect Effects 0.000 description 12
- 230000002797 proteolythic effect Effects 0.000 description 12
- 239000000758 substrate Substances 0.000 description 12
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 11
- 241000239370 Euphausia superba Species 0.000 description 11
- 208000001860 Eye Infections Diseases 0.000 description 11
- 208000025865 Ulcer Diseases 0.000 description 11
- 235000015110 jellies Nutrition 0.000 description 11
- 230000004044 response Effects 0.000 description 11
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 10
- 239000004365 Protease Substances 0.000 description 10
- 206010039491 Sarcoma Diseases 0.000 description 10
- 208000033809 Suppuration Diseases 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 210000002435 tendon Anatomy 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 102000009123 Fibrin Human genes 0.000 description 9
- 108010073385 Fibrin Proteins 0.000 description 9
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 9
- 208000032843 Hemorrhage Diseases 0.000 description 9
- 206010000496 acne Diseases 0.000 description 9
- 230000000740 bleeding effect Effects 0.000 description 9
- 230000015556 catabolic process Effects 0.000 description 9
- 229950003499 fibrin Drugs 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 230000035876 healing Effects 0.000 description 9
- 238000007912 intraperitoneal administration Methods 0.000 description 9
- 239000008274 jelly Substances 0.000 description 9
- 235000019419 proteases Nutrition 0.000 description 9
- 241000283690 Bos taurus Species 0.000 description 8
- 206010017533 Fungal infection Diseases 0.000 description 8
- 208000002260 Keloid Diseases 0.000 description 8
- 208000031888 Mycoses Diseases 0.000 description 8
- 208000036142 Viral infection Diseases 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- 238000006731 degradation reaction Methods 0.000 description 8
- 208000011323 eye infectious disease Diseases 0.000 description 8
- 210000001117 keloid Anatomy 0.000 description 8
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 8
- 239000012460 protein solution Substances 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 230000009385 viral infection Effects 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 206010027476 Metastases Diseases 0.000 description 7
- 206010030113 Oedema Diseases 0.000 description 7
- 208000007536 Thrombosis Diseases 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 230000009471 action Effects 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 210000003953 foreskin Anatomy 0.000 description 7
- 230000007124 immune defense Effects 0.000 description 7
- 210000002414 leg Anatomy 0.000 description 7
- 239000002324 mouth wash Substances 0.000 description 7
- 229940051866 mouthwash Drugs 0.000 description 7
- 231100000241 scar Toxicity 0.000 description 7
- 231100000397 ulcer Toxicity 0.000 description 7
- 206010018785 Gingival infections Diseases 0.000 description 6
- 208000009889 Herpes Simplex Diseases 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000005755 formation reaction Methods 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- 208000035143 Bacterial infection Diseases 0.000 description 5
- 208000010201 Exanthema Diseases 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 201000004681 Psoriasis Diseases 0.000 description 5
- 230000000845 anti-microbial effect Effects 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 208000022362 bacterial infectious disease Diseases 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 201000005884 exanthem Diseases 0.000 description 5
- 210000002865 immune cell Anatomy 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 230000007794 irritation Effects 0.000 description 5
- 210000003127 knee Anatomy 0.000 description 5
- 229960004857 mitomycin Drugs 0.000 description 5
- 206010037844 rash Diseases 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 210000003954 umbilical cord Anatomy 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- 239000008215 water for injection Substances 0.000 description 5
- 208000002177 Cataract Diseases 0.000 description 4
- 208000032544 Cicatrix Diseases 0.000 description 4
- 241000208317 Petroselinum Species 0.000 description 4
- 208000002847 Surgical Wound Diseases 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 4
- 229960004316 cisplatin Drugs 0.000 description 4
- 229940079919 digestives enzyme preparation Drugs 0.000 description 4
- 239000006196 drop Substances 0.000 description 4
- 229960005102 foscarnet Drugs 0.000 description 4
- 239000000416 hydrocolloid Substances 0.000 description 4
- 210000004347 intestinal mucosa Anatomy 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- 230000001926 lymphatic effect Effects 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 235000011197 perejil Nutrition 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000037387 scars Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 238000010254 subcutaneous injection Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000012085 test solution Substances 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 208000019206 urinary tract infection Diseases 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010023330 Keloid scar Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 206010028851 Necrosis Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 239000000287 crude extract Substances 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000003889 eye drop Substances 0.000 description 3
- 229940012356 eye drops Drugs 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 210000005075 mammary gland Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 230000027939 micturition Effects 0.000 description 3
- 210000003097 mucus Anatomy 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 230000008058 pain sensation Effects 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 3
- 230000000306 recurrent effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 210000003708 urethra Anatomy 0.000 description 3
- 210000003932 urinary bladder Anatomy 0.000 description 3
- 210000000707 wrist Anatomy 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 208000002881 Colic Diseases 0.000 description 2
- 241000777300 Congiopodidae Species 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 206010014190 Eczema asteatotic Diseases 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 2
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 2
- 206010028470 Mycoplasma infections Diseases 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 206010039424 Salivary hypersecretion Diseases 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000002474 Tinea Diseases 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 208000000260 Warts Diseases 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 229940009456 adriamycin Drugs 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000007541 cellular toxicity Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 201000004946 genital herpes Diseases 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 230000036074 healthy skin Effects 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- 239000007922 nasal spray Substances 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 210000004224 pleura Anatomy 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 208000026451 salivation Diseases 0.000 description 2
- 230000036573 scar formation Effects 0.000 description 2
- 230000037307 sensitive skin Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 201000010153 skin papilloma Diseases 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 230000001810 trypsinlike Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 101710150620 Anionic peptide Proteins 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 102000000496 Carboxypeptidases A Human genes 0.000 description 1
- 108010080937 Carboxypeptidases A Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 208000034657 Convalescence Diseases 0.000 description 1
- 206010063057 Cystitis noninfective Diseases 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 241001516614 Exema Species 0.000 description 1
- 206010015946 Eye irritation Diseases 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 206010061190 Haemophilus infection Diseases 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 208000001688 Herpes Genitalis Diseases 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 208000001294 Nociceptive Pain Diseases 0.000 description 1
- 240000001090 Papaver somniferum Species 0.000 description 1
- 235000008753 Papaver somniferum Nutrition 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 206010051077 Post procedural haemorrhage Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000019155 Radiation injury Diseases 0.000 description 1
- 208000004680 Rectal Fistula Diseases 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 206010043248 Tendon rupture Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 208000031294 Upper limb fractures Diseases 0.000 description 1
- 206010047482 Viral upper respiratory tract infection Diseases 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 208000026816 acute arthritis Diseases 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 239000011717 all-trans-retinol Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 206010002156 anal fistula Diseases 0.000 description 1
- 206010002168 anal polyp Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 231100000013 eye irritation Toxicity 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000010200 folin Substances 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 231100000171 higher toxicity Toxicity 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 244000145841 kine Species 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000013469 light sensitivity Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000022766 lymph node neoplasm Diseases 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 240000004308 marijuana Species 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- RGOVYLWUIBMPGK-UHFFFAOYSA-N nonivamide Chemical compound CCCCCCCCC(=O)NCC1=CC=C(O)C(OC)=C1 RGOVYLWUIBMPGK-UHFFFAOYSA-N 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940066734 peptide hydrolases Drugs 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 230000001543 purgative effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000009418 renovation Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 208000026775 severe diarrhea Diseases 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002522 swelling effect Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 230000003813 thin hair Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 231100000925 very toxic Toxicity 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Birds (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9201628A SE9201628D0 (sv) | 1992-05-22 | 1992-05-22 | Pharmaceutical composition |
| PCT/SE1993/000455 WO1993024142A1 (en) | 1992-05-22 | 1993-05-21 | New pharmaceutical uses of krill enzymes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK140594A3 true SK140594A3 (en) | 1996-10-02 |
Family
ID=20386327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1405-94A SK140594A3 (en) | 1992-05-22 | 1993-05-21 | Manufacture and application of non-immunogenic enzymatic pharmaceutical agents isolated from antarctic krill |
Country Status (18)
| Country | Link |
|---|---|
| EP (3) | EP0838213B1 (es) |
| JP (2) | JPH08501068A (es) |
| KR (1) | KR100290266B1 (es) |
| CN (1) | CN1090507C (es) |
| AT (2) | ATE214610T1 (es) |
| AU (1) | AU675942B2 (es) |
| CA (2) | CA2136331C (es) |
| CZ (1) | CZ286794A3 (es) |
| DE (2) | DE69333931T2 (es) |
| DK (1) | DK0642351T3 (es) |
| ES (2) | ES2255097T3 (es) |
| HU (1) | HUT69989A (es) |
| NO (1) | NO944448L (es) |
| RU (1) | RU94046254A (es) |
| SE (1) | SE9201628D0 (es) |
| SK (1) | SK140594A3 (es) |
| WO (1) | WO1993024142A1 (es) |
| ZA (1) | ZA933598B (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5945102A (en) * | 1994-11-22 | 1999-08-31 | Phairson Medical Inc. | Crustacean and fish derived multifunctional enzyme |
| US7947270B2 (en) | 1992-05-22 | 2011-05-24 | Arcimboldo Ab | Removing dental plaque with krill enzymes |
| US5958406A (en) * | 1994-11-22 | 1999-09-28 | Phairson Medical Inc. | Acne treatment with multifunctional enzyme |
| US6030612A (en) * | 1994-11-22 | 2000-02-29 | Phairson Medical Inc. | Antimicrobial uses of multifunctional enzyme |
| SE9303899D0 (sv) * | 1993-11-22 | 1993-11-22 | Phairson Medical Inc | Läkemedel |
| WO1995033471A1 (en) * | 1994-06-07 | 1995-12-14 | Hellgren, Lars | Intravasal thrombolysis |
| AU700252B2 (en) * | 1994-06-07 | 1998-12-24 | Antarctic Pharma Ab | Composition for dental use comprising krill enzyme |
| US6232088B1 (en) | 1995-02-08 | 2001-05-15 | Phairson Medical, Inc. | Treatment and prevention of immune rejection reactions |
| US6040155A (en) * | 1996-08-28 | 2000-03-21 | Kay; John | Multifunctional protein and DNA sequence encoding same |
| US6835385B2 (en) * | 2002-06-14 | 2004-12-28 | Carol J. Buck | Compositions and methods for softening, thinning and removing hyperkeratotic tissue |
| DE10237317B4 (de) | 2002-08-15 | 2010-04-08 | 3M Espe Ag | Enzymhaltige Zusammensetzung, Verfahren zu deren Herstellung und deren Verwendung |
| US7332179B2 (en) | 2003-12-12 | 2008-02-19 | Kimberly-Clark Worldwide, Inc. | Tissue products comprising a cleansing composition |
| EP1600141B1 (en) | 2004-05-24 | 2013-04-17 | 3M Deutschland GmbH | Collagenolytic active enzyme containing compositions for the treatment of dental caries |
| US9023323B2 (en) * | 2004-12-16 | 2015-05-05 | Colgate-Palmolive Company | Oral compositions for prevention and reduction of bacterial adhesion to oral surfaces |
| US8894977B2 (en) | 2004-12-16 | 2014-11-25 | Colgate-Palmolive Company | Oral treatment compositions containing an anti-adhesion agent, antibacterial agent and incompatible compound |
| US7642395B2 (en) | 2004-12-28 | 2010-01-05 | Kimberly-Clark Worldwide, Inc. | Composition and wipe for reducing viscosity of viscoelastic bodily fluids |
| EP2144618B1 (en) | 2007-03-28 | 2013-05-15 | Aker Biomarine ASA | Bioeffective krill oil compositions |
| US8697138B2 (en) | 2007-03-28 | 2014-04-15 | Aker Biomarine As | Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders |
| US8372812B2 (en) | 2009-02-26 | 2013-02-12 | Aker Biomarine Asa | Phospholipid and protein tablets |
| AU2014203179C1 (en) | 2013-06-14 | 2017-05-04 | Aker Biomarine Antarctic As | Lipid extraction processes |
| GB201400431D0 (en) | 2014-01-10 | 2014-02-26 | Aker Biomarine As | Phospholipid compositions and their preparation |
| EP3256003B1 (en) | 2015-02-11 | 2022-11-09 | Aker Biomarine Antarctic AS | Lipid extraction processes |
| KR102079747B1 (ko) | 2015-02-11 | 2020-02-20 | 에이커 바이오마린 앤탁틱 에이에스 | 지질 조성물 |
| CN113429458B (zh) * | 2021-08-03 | 2022-07-01 | 浙江海洋大学 | 一种抑制二肽基肽酶iv功能的南极磷虾降血糖寡肽及用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0107634B1 (en) * | 1982-10-25 | 1989-04-12 | Lars Gustav Inge Hellgren | Enzyme composition for cleaning, the use thereof and preparation of the composition |
| JPS6130527A (ja) * | 1984-07-20 | 1986-02-12 | Kao Corp | 血栓溶解剤 |
| JP2568833B2 (ja) * | 1987-02-27 | 1997-01-08 | 大洋香料株式会社 | う蝕予防剤 |
| JPS63218610A (ja) * | 1987-03-09 | 1988-09-12 | Hayashikane Sangyo Kk | プロテア−ゼ配合化粧品 |
| JPH06168418A (ja) * | 1992-11-26 | 1994-06-14 | Matsushita Electric Ind Co Ltd | 薄膜磁気ヘッド |
-
1992
- 1992-05-22 SE SE9201628A patent/SE9201628D0/xx unknown
-
1993
- 1993-05-21 DE DE69333931T patent/DE69333931T2/de not_active Expired - Lifetime
- 1993-05-21 CA CA002136331A patent/CA2136331C/en not_active Expired - Fee Related
- 1993-05-21 SK SK1405-94A patent/SK140594A3/sk unknown
- 1993-05-21 AU AU41000/93A patent/AU675942B2/en not_active Ceased
- 1993-05-21 DK DK93910549T patent/DK0642351T3/da active
- 1993-05-21 KR KR1019940704201A patent/KR100290266B1/ko not_active IP Right Cessation
- 1993-05-21 DE DE69331739T patent/DE69331739T2/de not_active Expired - Fee Related
- 1993-05-21 RU RU94046254/14A patent/RU94046254A/ru unknown
- 1993-05-21 HU HU9403343A patent/HUT69989A/hu unknown
- 1993-05-21 EP EP97202796A patent/EP0838213B1/en not_active Expired - Lifetime
- 1993-05-21 JP JP6500454A patent/JPH08501068A/ja active Pending
- 1993-05-21 ES ES97202796T patent/ES2255097T3/es not_active Expired - Lifetime
- 1993-05-21 CA CA002306952A patent/CA2306952A1/en not_active Abandoned
- 1993-05-21 ES ES93910549T patent/ES2173887T3/es not_active Expired - Lifetime
- 1993-05-21 WO PCT/SE1993/000455 patent/WO1993024142A1/en not_active Application Discontinuation
- 1993-05-21 AT AT93910549T patent/ATE214610T1/de not_active IP Right Cessation
- 1993-05-21 EP EP93910549A patent/EP0642351B1/en not_active Expired - Lifetime
- 1993-05-21 CZ CZ942867A patent/CZ286794A3/cs unknown
- 1993-05-21 EP EP97202849A patent/EP0824910A3/en not_active Withdrawn
- 1993-05-21 AT AT97202796T patent/ATE311853T1/de not_active IP Right Cessation
- 1993-05-22 CN CN93108207A patent/CN1090507C/zh not_active Expired - Fee Related
- 1993-05-24 ZA ZA933598A patent/ZA933598B/xx unknown
-
1994
- 1994-11-21 NO NO944448A patent/NO944448L/no unknown
-
2000
- 2000-05-19 JP JP2000147259A patent/JP4012665B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK140594A3 (en) | Manufacture and application of non-immunogenic enzymatic pharmaceutical agents isolated from antarctic krill | |
| AU718220B2 (en) | Multifunctional enzyme | |
| JP5646446B2 (ja) | 医療用化合物あるいは医療用製品を作成するための生体適合性ポリマーの使用方法 | |
| CZ9300229A3 (cs) | Kombinační prostředky pro léčení bazocelulárního karcinomu nebo aktinických keratóz | |
| US5958406A (en) | Acne treatment with multifunctional enzyme | |
| CN1889965B (zh) | 使用生物相容聚合物,制备一种化合物或制造一种医用设备 | |
| US4497824A (en) | Method of chemically debriding ulcerated necrotic tissue | |
| US4469702A (en) | Analgesic composition and use thereof to ameliorate deep and intractable pain | |
| US20060134641A1 (en) | Treating viral infections with krill enzymes | |
| US7947270B2 (en) | Removing dental plaque with krill enzymes | |
| RU2149644C1 (ru) | Способ лечения заболеваний, сопровождающихся образованием гноя и/или некротических тканей | |
| Groves | A Synopsis of Surgery | |
| RU2161503C2 (ru) | Лечебное средство | |
| Mills et al. | A text-book of surgery for dental students | |
| Edwards | Cyclopaedia of the Diseases of Children, Medical and Surgical | |
| Luxenburger | Clinical and Experimental Use of Orthoform | |
| Cunning | Aids to surgery |